- Home
- FTHM vs RNXT Comparison
FTHM vs RNXT Comparison
Compare FTHM & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTHM
- RNXT
- Stock Information
- Founded
- FTHM 2010
- RNXT 2012
- Country
- FTHM United States
- RNXT United States
- Employees
- FTHM N/A
- RNXT N/A
- Industry
- FTHM Real Estate
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- FTHM Finance
- RNXT Health Care
- Exchange
- FTHM Nasdaq
- RNXT Nasdaq
- Market Cap
- FTHM 27.1M
- RNXT 34.0M
- IPO Year
- FTHM 2020
- RNXT 2021
- Fundamental
- Price
- FTHM $0.80
- RNXT $1.02
- Analyst Decision
- FTHM Strong Buy
- RNXT Strong Buy
- Analyst Count
- FTHM 4
- RNXT 1
- Target Price
- FTHM $4.25
- RNXT $9.00
- AVG Volume (30 Days)
- FTHM 89.3K
- RNXT 140.5K
- Earning Date
- FTHM 05-08-2025
- RNXT 05-09-2025
- Dividend Yield
- FTHM N/A
- RNXT N/A
- EPS Growth
- FTHM N/A
- RNXT N/A
- EPS
- FTHM N/A
- RNXT N/A
- Revenue
- FTHM $317,515,000.00
- RNXT N/A
- Revenue This Year
- FTHM N/A
- RNXT N/A
- Revenue Next Year
- FTHM $26.34
- RNXT N/A
- P/E Ratio
- FTHM N/A
- RNXT N/A
- Revenue Growth
- FTHM N/A
- RNXT N/A
- 52 Week Low
- FTHM $0.70
- RNXT $0.77
- 52 Week High
- FTHM $3.37
- RNXT $1.82
- Technical
- Relative Strength Index (RSI)
- FTHM 23.37
- RNXT 36.81
- Support Level
- FTHM $0.70
- RNXT $0.91
- Resistance Level
- FTHM $0.86
- RNXT $1.03
- Average True Range (ATR)
- FTHM 0.10
- RNXT 0.06
- MACD
- FTHM -0.01
- RNXT 0.00
- Stochastic Oscillator
- FTHM 1.42
- RNXT 30.95
About FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, insurance, and Software as a Service offering to brokerages and agents by leveraging proprietary cloud-based software, intelliAgent. The company has three reportable segments namely Real Estate Brokerage, Mortgage and Technology. The brands of the company include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.